author-photo

Poulikos I. Poulikakos

Icahn School of Medicine at Mount Sinai
Memorial Sloan Kettering Cancer Center

59

Papers

6752

Citations

Citation Trend

Filter By

Papers (44) Sort By

Journal Conference Others

P-090: BRAF V600E multiple myeloma patient salvaged with triple MAPK inhibition after CAR T relapse

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (4)
Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6

2021
Show All
- Source
- Cite
- Save
Citations (0)
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

2021
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 78: A strategy for effective targeting of oncogenic BRAF signaling with increased therapeutic index using conformation-selective RAF and MEK inhibitors

2021
Show All
- Source
- Cite
- Save
Citations (0)
AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (0)
Inhibitors of BRAF dimers using an allosteric site.

2020 Nature Communications
Show All
- Source
- Cite
- Save
Citations (13)
SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors

2019 Cell Reports
Show All
- Source
- Cite
- Save
Citations (72)
Abstract CN05-02: Next generation strategies to overcome adaptive resistance to MAPK-directed therapies

2019 Molecular Cancer Therapeutics
- Poulikos I. Poulikakos
Show All
- Source
- Cite
- Save
Citations (0)